anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Therapeutic interventions for the recovery of hand function after a neurological injury have historically been very limited. A significant body of research now supports the use of an upper extremity retraining approach for functional recovery after neurological injury. Few therapeutic approaches offer any intervention specifically focused on grasp and release retraining. In an effort to address this deficit, the SaeboFlex dynamic hand orthosis was developed by occupational therapists. The F.T.M. Arm Training Program has been safely used by hundreds of occupational and physical therapists on over one thousand patients in outpatient neurological rehabilitation over the last 2 years. It is currently an accepted modality of treatment for the management of hand paresis in the acquired brain injury outpatient population. Two factors, other than the severity of the initial injury, have been clinically identified as having a significant affect on the outcomes achieved in F.T.M. Arm Training treatment. They are learned non-use and soft tissue shortening of the finger flexors. All treatment delivered to the subjects that partake in this study will be clinical care and the only research component of this study will be the assessment of outcomes. The purpose of this study is to explore the potential patient population that may qualify to use the SaeboFlex Dynamic Hand Orthosis as a therapeutic option in the inpatient population.
The present disclosure provides topical skin formulations including sunscreen compositions and cannabidiol compositions. The present disclosure further provides topical skin formulations including both sunscreen agents and cannabidiol. The sunscreen agents are included in an amount from about 0.01 to 20% by weight. Cannabidiol is included in an amount from about 0.01 to 10% by weight. A method for applying multiple topical skin formulations includes separately storing a sunscreen composition and a cannabidiol composition in a multi-chambered device. The multi-chambered device may be configured to dispense each composition independently of the other or simultaneously in adjustable ratios.
MET-5 is a new product composed of twenty-six strains of bacteria isolated from the stool of a different healthy donor than MET-3. Although it is expected to work in a similar fashion to MET-3, it contains some strains that are unique in comparison to the original MET-3 formulation and have been associated with leanness in the scientific literature. MET-5 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
The precipitant for adult posttraumatic stress disorder (PTSD) is a known event, which allows for immediate intervention and presents the potential to prevent the occurrence of this serious condition. However, there currently are no accepted interventions for the early intervention and prevention of PTSD in the immediate aftermath of trauma. This study will determine whether providing exposure therapy to people who have recently experienced trauma will significantly reduce the severity of PTSD symptoms post-trauma and if delivery of three exposure sessions will result in larger reductions in the symptoms of PTSD post-trauma than one exposure session. This study will also examine predictors for treatment response.

Participation in this study will last 12 months. Participants will first undergo an evaluation session that will include an interview and questionnaires. They will then be randomly assigned to one of the following three conditions: 1-session exposure therapy, 3-session exposure therapy, or assessment only. Participants receiving 1-session exposure therapy will complete one treatment session in the emergency department (ED). Participants receiving 3-session exposure therapy will complete three weekly treatment sessions, with the first occurring in the ED. Treatment will involve reviewing memories of a recent trauma out loud with a therapist and audio-recording these discussions for review at home. All participants will undergo assessments 1, 3, 6, and 12 months after the initial evaluation session.
Cestodes are etiological agents of neglected diseases such as echinococcosis and cysticercosis, which are major public health problems. Antiparasitic treatment relies on a small number of approved drugs, which are often only partially effective, poorly tolerated and require prolonged administration. Thus, the discovery of novel potential treatments is critical. The Stevia genus (Asteraceae) includes species that are recognized as a source of bioactive compounds, with many species associated with medicinal uses. In this study, the cestocidal activity of four South American Stevia species that previously showed antiprotozoal activity was analyzed using a motility assay on the laboratory cestode model, Mesocestoides vogae. The four Stevia extracts showed cestocidal activity, with S. alpina var. alpina as the most active. The sesquiterpene lactones estafietin and eupatoriopicrin were purified from S. alpina var. alpina and S. maimarensis, respectively, and tested on M. vogae. Estafietin showed cestocidal activity, inhibiting parasite viability in a dose-dependent manner, even from the first day of incubation. Consistent with the motility effects, the extract of S. alpina var. alpina and estafietin induced marked alterations in the morphology of the parasite. The results of this report show that Stevia species represent a source of new molecules with potential for the treatment of neglected tropical diseases caused by cestodes.
Therapeutic options for advanced prostate cancer have vastly expanded over the last decade and will continue to expand in the future. Drugs targeting the androgen receptor (AR) signaling pathway, i.e., androgen receptor targeting agents (ARTAs), remain the mainstream treatments that are increasingly transforming the disease into one that can be controlled for an extended period of time. Prostate cancer is inherently addicted to AR. Under the treatment pressure of ARTA, molecular alterations occur, leading to the clonal expansion of resistant cells in a disease state broadly categorized as castration-resistant prostate cancer (CRPC). One castration resistance mechanism involves AR splice variants (AR-Vs) lacking the ligand-binding domain. Some AR-Vs have been identified as constitutively active, capable of activating AR signaling pathways without androgenic ligands. Among these variants, AR-V7 is the most extensively studied and may be measured non-invasively using validated circulating tumor cell (CTC) tests. In the context of the evolving prostate cancer treatment landscape, novel agents are developed and evaluated for their efficacy in targeting AR-V7. In patients with metastatic CRPC (mCRPC), the availability of the AR-V7 tests will make it possible to determine whether the treatments are effective for CTC AR-V7-positive disease, even though the treatments may not be specifically designed to target AR-V7. In this review, we will first outline the current prostate cancer treatment landscape, followed by an in-depth review of relatively newer prostate cancer therapeutics, focusing on AR-targeting agents under clinical development. These drugs are categorized from the standpoint of their activities against AR-V7 through direct or indirect mechanisms.
PURPOSE: Perioperative bleeding is a serious concern during orthognathic surgery. Tranexamic acid (TXA), a synthetic lysine analog with antifibrinolytic properties, reduces blood loss across various surgical fields. This study aimed to investigate the effectiveness of preoperative TXA administration in reducing intraoperative and postoperative blood loss following combined Le Fort I and sagittal split ramus osteotomies at our hospital.
METHODS: This single-center, retrospective cohort study included patients who underwent combined Le Fort I and sagittal split ramus osteotomies between November 2017 and October 2022. The primary outcome was the volume of intraoperative blood loss.
RESULTS: Among 1,329 eligible patients, 87 were included in the analysis (32 in the TXA group and 55 in the control group, where no TXA was administered). The median (interquartile range) intraoperative blood loss was 200.0 (157.5-237.5) mL in the TXA group and 260.0 (180.0-350.0) mL in the control group, showing a significant difference between the groups (p = 0.0365). However, postoperative blood drainage within 24 h and 24-48 h did not differ significantly between the two groups.
CONCLUSION: A single intravenous administration of TXA was associated with a decrease in intraoperative bleeding without severe adverse events during combined Le Fort I and sagittal split ramus osteotomies. However, postoperative blood loss, nausea, vomiting, and autologous blood transfusion were not significantly associated with this administration.
A method for detection, treatment, and prevention of neurological development disorders utilizes an infrared imaging device, meridian theory of traditional Chinese medicine, and predetermined amounts of solid water particles to detect, treat, and prevent a neurological developmental disorder, such as autism. The method detects the disorder by initially identifying at least one hot spot on a patient with an infrared imaging device. At least one acupoint along a meridian pathway is identified. The hot spot is correlated with at least one acupoint located along the meridian pathway. The nexus of the hot spot and the meridian pathway indicates a potential neurological development disorder. A degree of irregularity of the internal organ is discerned by measuring a quantitative temperature at the nexus. A solid water particle is applied through a delivery means, such as oral, topical, vapor, and intravenous administration for treatment of the neurological developmental disorder.
Adult stem cell therapy via intramyocardial injection of autologous CD34+ stem cells has been shown to improve exercise capacity and reduce angina frequency and mortality in patients with refractory angina (RA). However, the cost of such therapy is a limitation to its adoption in clinical practice. Our goal was to determine whether the less costly, less invasive, and widely accessible, FDA-approved alternative treatment for RA patients, known as enhanced external counterpulsation (EECP), mobilizes endogenous CD34+ stem cells and whether such mobilization is associated with the clinical benefits seen with intramyocardial injection. We monitored changes in circulating levels of CD34+/CD133+ and CD34+/KDR+ cells in RA patients undergoing EECP therapy and in a comparator cohort of RA patients undergoing an exercise regimen known as cardiac rehabilitation. Changes in exercise capacity in both cohorts were monitored by measuring treadmill times (TT), double product (DP) scores, and Canadian Cardiovascular Society (CCS) angina scores between pre- and post-treatment treadmill stress tests. Circulating levels of CD34+/CD133+ cells increased in patients undergoing EECP and were significant (β = -2.38, p = 0.012) predictors of improved exercise capacity in these patients. CD34+/CD133+ cells isolated from RA patients could differentiate into endothelial cells, and their numbers increased during EECP therapy. Our results support the hypothesis that mobilized CD34+/CD133+ cells repair vascular damage and increase collateral circulation in RA patients. They further support clinical interventions that can mobilize adult CD34+ stem cells as therapy for patients with RA and other vascular diseases.
Phase I- Bevacizumab will be administered intravenously every other week. Temozolomide will be administered on a continuous daily dosing schedule. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen.
For patients with epilepsy, one of the biggest problems is the unpredictability of the time when the next seizure will occur. Interestingly, some epileptic patients experience a sensory sensation preceding seizures, called aura, which helps them move to safety before a seizure. Here, we describe the development of the first animal model of auras, which could allow for a more detailed study of this phenomenon. Specifically, in mice, we presented sensory stimuli (sound and light cues) a few seconds before kindling an animal to induce seizures. Animals were kindled by electrical stimulation in the basolateral amygdalar nucleus. Over the course of stimulation sessions, animals started showing progressively stronger freezing behavior to sensory cues preceding kindling. Interestingly, seizures are known to cause retrograde amnesia, thus it was surprising that the association between seizures and preceding sensory cues developed in all experimental animals. In summary, our experiments show that similarly to auras, a sensory sensation can be associated with incoming generalized seizures and is not erased by retrograde amnesia.
The invention discloses a new traditional Chinese medicine composition for treating liver ascites symptoms and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared from the following medicine components: cassia twig, tuckahoe, rhizoma alismatis, Plantain seed, fiveleaf akebia, Lobelia, mulberry bark, climbing fern spore, broom cypress fruit, lysimachia, talcum, notopterygium root, ledebouriella root, acanthopanax bark, orientvine, cinnamon, clove, pangolin, dried orange peer, immature bitter orange, nut grass, rhubarb, hemlock parsley, magnolia bark, Chinese yam, white atractylodes rhizome, semen raphani, japanese sweetflag, bush-cherry seed, angelica glabra, Evodia rutaecarpa, galangal, allium macrostemon, Semen Euryales, pyrrosia lingua, ricepaperplant and oriental wormwood. The traditional Chinese medicine composition can be prepared into any commonly-used oral preparation by using the conventional traditional Chinese medicine preparation method. The invention can obviously improve the symptoms of abdominal distention, ascites, difficulty in walking, and probable obvious diaphragm elevation with expiratory dyspnea and exomphalocele before the ocurrence of ascites. Some patients possibly have the symptoms of hydrothorax, increased portal venous pressure, increased hydrostatic pressure abdominal visceral vessel beds, hypoalbuminemia diseases, excessive lymphogenesis, secondary hyperaldosteronism, reduction of renal blood flow, sodium output and urinary output and the like. The traditional Chinese medicine composition has exact and obvious clinical curative effect and high efficiency. By basically combining edible and pharmaceutical products specified in the national pharmacopoeia, the traditional Chinese medicine composition has the advantages of low cost, no toxic or side effects and the like.
PURPOSE: Provided is a composition containing the extract of specially treated ginseng for preventing and treating brain stroke. The composition has strengthened pharmacological efficacy of the ginseng to protect brain cells and is widely used for remedies and health foods. CONSTITUTION: The composition for preventing and treating brain stroke is characterized by containing, as active ingredient, the extract of ginseng that is specifically treated with acids including acetic acid, citric acid, lactic acid and the like as well as lactic acid bacteria, such as Bifidobacterium sp. or Lactobacillus sp. strains or enteric bacteria, such as Bacterioides sp. or Fusobacterium sp. strains. The composition is formulated into powers, granules, capsules, liquid and injection.
A tumor radiation probe of iodine-123 marker thymidine (FLT) analogue [ 123 I]-IaraU is disclosed. Commercial available uridine is used as the raw material for the synthesis of the precursor. A radioactive iodine-123 is marked on an alkaline group of uridine to obtain [ 123 I]-IaraU, which is distinguishable from [ 18 F]-FLT marking  18 F on a glycosyl group to obtain a novel tumor radiation probe. The marking procedures include mixing the marker precursor with Na [ 123 I] solution, acetic acid and hydrogen peroxide solution, and the solution of chloroform and sodium hydroxide. The sonication time increases from 1 minute to 10 minutes, so that [ 123 I]-IaraU has radiologically chemical purity of higher than 98% and radiological specific activity of not less than 0.196 GBq/umole, and the yield can increase from 8% to 40%. Its radioactive specific activity, yield and purity reach to the degree for the use in biological experiments, while reducing production cost.
PURPOSE: A skin whitening method for cosmetic treatment is provided to reduce the recovery period of the skin and to enhance the satisfaction about the recovery. CONSTITUTION: A skin whitening method for cosmetic treatment is as follows. A laser is irradiated to a pigment site of a patient until the color of the pigment site is changed. The blood of the patient is collected and preserved. The preserved blood is separated by a centrifugal separator. Only the first serum ingredient is collected. The serum ingredient is secondly separated by the centrifugal separator. The second serum ingredient is collected. A PRP(Platelet Rich Plasma) liquid is created by mixing the second serum ingredient with CaCl2. The PRP liquid is spread in the discolored pigment site of the patient. A micro hole is formed on the skin. The PRP liquid is spread on the skin in which the micro hole is formed. The skin is pacified.
QT/QTc interval prolongation is investigated during the first two weeks of subject participation in the parallel phase 3 study. The pre-cordial leads and lead II will be utilized to determine QT/QTc prolongation. Descriptive information is provided on changes in T and U wave morphologies. The percentage of subjects in each therapy group who have worsening of the T and U wave morphology is documented. Discrete U waves are excluded from the QT/QTc interval measurement. Except for the pre-therapy ECGs, all ECGs are performed during one ANP therapy infusion daily, that being an afternoon infusion to account for diurnal variation in the QT/QTc interval. The study subject is at rest in the supine position for 30 minutes prior to the ECG study. The baseline QTc is derived from 3 ECGs taken on day 1 during the hour preceding the first Antineoplaston therapy infusion or the first radiation session.
Participants were asked to use Moving Through Glass (MTG) intervention on Google Glass for at least once a day for 3 weeks. MTG intervention includes 4 difference guided-dance/movement modules for the participants.
In order to overexpress a Stx2eA2-monomer-Stx2eB pentamer recombinant protein among Stx2e toxins, which is one of the causes of edema in pigs, the Stx2eA2 gene and the Stx2eB gene are cloned into pTWIN1 and pET30a, respectively, and then these vectors are cloned into E.coliBL21(DE3)pLysS is transformed. When five monomers Stx2eB expressed from the Stx2eB gene are gathered, a pentagonal structure is formed to form a Stx2eB pentamer, and the pentameric Stx2eB and Stx2eA2 monomers combine to produce a stable Stx2eA2-monomer-Stx2eB-pentameric recombinant protein. The overexpressed Stx2eA2 fragment-Stx2eB pentameric recombinant protein and IMS 1313 adjuvant are mixed with IMS 1313 adjuvant as an antigen to prevent edema. When piglets are 5 days old and 3 weeks old, they were inoculated intramuscularly, respectively. After inoculation, a significant antibody titer is observed in piglets of a group inoculated with 75 ug of Stx2eA2-monomer-Stx2eB-pentamer recombinant protein compared to a control group, and edema disease or weaning piglets in the group inoculated with Stx2eA2-monomer-Stx2eB-pentamer recombinant protein 75ug. No clinical symptoms of diarrheal disease and no mortality are observed. Therefore, the vaccine containing the recombinant Stx2eA2-monomer and Stx2eB pentamer protein of the present invention is expected to be useful as a toxoid vaccine capable of preventing edema in pigs.
After periodontal examination, samples were collected from all patients via informing them about procedures. Then all samples were stored at -80 C unto analyses.
PURPOSE: An Id1 protein for preventing or treating fibrosis is provided to relieve symptom due to collagen synthesis and to reduce collagen expression induced by TGF-beta 1/Smad 2,3. CONSTITUTION: A pharmaceutical composition for preventing or treating fibrosis contains Id1(inhibitory of DNA binding 1) protein or a polynucleotide encoding the protein as an active ingredient. The protein is Id1-v2 having an amino acid sequence of sequence number 1. A polynucleotide encoding the protein has a base of sequence number 2. An expression vector contains the polynucleotide. The expression vector is a retrovirus vector or adenovirus vector. A method for screening a candidate material for preventing or treating fibrosis comprises: a step of contacting a candidate material to Id1 protein or a recombinant cells expressing the protein; a step of measuring Id1 protein level and activation or gene expression level; and a step of determining the candidate material is the material for preventing or treating fibrosis in case of the expression level and activation is increased over a control group.
BACKGROUND: Invasive bacterial infections (IBIs) in febrile infants are rare but potentially devastating. We aimed to derive and validate a predictive model for IBI among febrile infants age 7-60 days.
METHODS: Data were abstracted retrospectively from electronic records of 37 emergency departments (EDs) for infants with a measured temperature >=100.4 F who underwent an ED evaluation with blood and urine cultures. Models to predict IBI were developed and validated respectively using a random 80/20 dataset split, including 10-fold cross-validation. We used precision recall curves as the classification metric.
RESULTS: Of 4411 eligible infants with a mean age of 37 days, 29% had characteristics that would likely have excluded them from existing risk stratification protocols. There were 196 patients with IBI (4.4%), including 43 (1.0%) with bacterial meningitis. Analytic approaches varied in performance characteristics (precision recall range 0.04-0.29, area under the curve range 0.5-0.84), with the XGBoost model demonstrating the best performance (0.29, 0.84). The five most important variables were serum white blood count, maximum temperature, absolute neutrophil count, absolute band count, and age in days.
CONCLUSION: A machine learning model (XGBoost) demonstrated the best performance in predicting a rare outcome among febrile infants, including those excluded from existing algorithms.
IMPACT: Several models for the risk stratification of febrile infants have been developed. There is a need for a preferred comprehensive model free from limitations and algorithm exclusions that accurately predicts IBIs. This is the first study to derive an all-inclusive predictive model for febrile infants aged 7-60 days in a community ED sample with IBI as a primary outcome. This machine learning model demonstrates potential for clinical utility in predicting IBI.
Transmasculine people usually reach amenorrhea within 6 months of adequate testosterone treatment. It is often assumed that no ovulation occurs during amenorrhea. However, in this study, we report recent ovulatory activity in amenorrheic transmasculine people on testosterone therapy at gender-affirming oophorectomy. Histological signs of recent ovulatory activity, including the presence of ovulatory follicles, corpus luteum, and corpus albicans, are observed in 17 of 52 individuals (33%). This is not significantly correlated to the duration, testosterone serum levels, or type of testosterone used. These results suggest that amenorrhea does not equal anovulation in transmasculine people on adequate testosterone therapy, emphasizing the importance of contraception for people who engage in sexual activity that can result in pregnancy.